Overview of the Surge#
Enliven Therapeutics (NASDAQ:ELVN) experienced a significant stock increase of 28% on Wednesday. This surge followed the announcement by Merck (NYSE:MRK) regarding its plans to acquire Terns Pharmaceuticals, a company focused on cancer treatments, in a deal valued at $6.7 billion.
Details of the Acquisition#
Merck's acquisition of Terns Pharmaceuticals will be executed at a price of $53.00 per share in cash. This valuation translates to an approximate equity value of $6.7 billion, or about $5.7 billion when accounting for Terns' cash reserves. The offer represents a 31% premium based on the average stock price over the last 60 days and a 42% premium over the last 90 days, indicating that Merck is paying significantly more than the recent market value of Terns' shares.
Focus on Terns' Lead Candidate#
The acquisition is primarily driven by Terns’ lead candidate, TERN-701. This innovative oral medication is designed to inhibit a specific protein involved in cancer cell growth and is currently being tested in a clinical trial for patients with a type of leukemia known as Philadelphia chromosome-positive chronic myeloid leukemia. In March 2024, the FDA granted TERN-701 Orphan Drug Designation, which can expedite its development and approval process due to its potential to treat a rare disease.
Enliven Therapeutics and Maze Therapeutics#
Enliven Therapeutics is a biopharmaceutical company that develops small molecule inhibitors aimed at treating cancer. Its clinical programs include ELVN-001, targeting chronic myeloid leukemia, and ELVN-002, aimed at non-small cell lung cancer. Additionally, Maze Therapeutics, another clinical-stage company, saw its shares rise by 10% as it focuses on developing precision medicines for various diseases, including obesity and cardiovascular conditions.